Visakhapatnam COVID Clinical Research Center set for vaccine trials from July
3 years, 6 months ago

Visakhapatnam COVID Clinical Research Center set for vaccine trials from July

Deccan Chronicle  

Visakhapatnam: The Visakhapatnam Covid Clinical Research Center will be ready to facilitate clinical trials by licensed pharma companies from July. We have almost got the center ready and are expecting clinical trials by vaccine manufacturing companies from July. The AMC handled clinical trials for Covishield vaccine in the first wave.” Dr Sudhakar further said that the biotechnology department would take care of the identification of licensed vaccine manufacturing companies and allot for their use different research centers in the country, including VCCRC. Now, we are ready with the sophisticated VCCRC, which was designed and created with advanced facilities and devices imported from countries like Germany.” VCCRC would be used for clinical research of any disease in future also, apart from the Covid, but the prime focus now would be on the Coronavirus, its new variants, vaccines and medicines.

Trials Clinical Research Clinical Trials Covid Vaccine Clinical Vccrc  center  rs  covid  centre  clinical  vccrc  amc  set  vaccine  visakhapatnam  companies  research  trials

History of this topic

Government funding work on four new COVID-19 vaccine candidates
3 years, 5 months ago

Government funding work on four new COVID-19 vaccine candidates

The Hindu  

The Centre is funding the development of four vaccines, which are currently in various stages of human trials. The government has also funded clinical trial sites, animal challenge facilities and immunoassay laboratories, all of which were collectively allotted a budget of ₹900 crore for 12 months, the Minister said. The four vaccines, being funded under Mission Covid Suraksha, were the …

Centre targets cumulative procurement of 187 crore doses of Covid vaccines by year-end
3 years, 6 months ago

Centre targets cumulative procurement of 187 crore doses of Covid vaccines by year-end

India Today  

Addressing the nation on Monday, Prime Minister Narendra Modi said the central government will now procure 75 per cent of all Covid vaccines produced in the country. The government's target is to have cumulatively procured 187.2 crore doses by year-end. According to the roadmap, 53.6 crore doses of Covid vaccines will be made available till July 31. Orders placed for …

Health ministry to buy 30 cr COVID-19 vaccine doses from Biological-E for Rs 1,500 cr
3 years, 6 months ago

Health ministry to buy 30 cr COVID-19 vaccine doses from Biological-E for Rs 1,500 cr

Firstpost  

The vaccine recently got the nod of approval for phase-3 clinical trials after showing promising results in phase 1 and 2. The Union Health Ministry has finalised arrangements with Hyderabad-based vaccine manufacturer Biological-E to reserve 30 crore COVID-19 vaccine doses for which it will be making an advance payment of Rs 1500 crore. The COVID-19 vaccine of Biological-E is currently …

Centre Seals Deal For Second Made-In-India Vaccine, Buys 30 Crore Doses From Hyderabad's Biological-E
3 years, 6 months ago

Centre Seals Deal For Second Made-In-India Vaccine, Buys 30 Crore Doses From Hyderabad's Biological-E

ABP News  

Covid Vaccine Update: In order to meet a strict vaccination target, the government has reserved 30 crore doses of Hyderabad-based Biological-Covid E's vaccine, which is still in clinical trials. The Health Ministry will make a 1,500-crore advance payment to the company for what will be the country's second made-in-India vaccine, following Bharat Biotech's Covaxin. Apart from Covaxin and Serum Institute …

Parliament panel had asked govt to ramp up production capacity of Covid vaccines in March
3 years, 7 months ago

Parliament panel had asked govt to ramp up production capacity of Covid vaccines in March

India Today  

A parliamentary standing committee had in March suggested ramping up of production capacity of two Covid vaccines manufactured in India to ensure their availability to a wider population as soon as possible after it was informed that there could be a "shortage" if the inoculation is opened beyond the priority groups. "The Committee.recommends.to strengthen.the efforts for ramping up the production …

Covid Task Force Head Says Vaccine Availability to Better from July. Till then, Bank on Masks, Tulsi, Haldi
3 years, 8 months ago

Covid Task Force Head Says Vaccine Availability to Better from July. Till then, Bank on Masks, Tulsi, Haldi

News 18  

Amid reports of shortage of Remedsivir in states, head of the national Covid task force, Dr VK Paul, has said that the drug should be used only in hospitals and not at pharma shops. Following Centre’s decision to fast track approvals for foreign-produced vaccines against coronavirus, the COVID task force head said India will witness a quantum increase in vaccinations …

Coronavirus | 6 crore COVID-19 vaccine doses sent to 76 nations, 4.5 crore doses administered in India: Harsh Vardhan
3 years, 9 months ago

Coronavirus | 6 crore COVID-19 vaccine doses sent to 76 nations, 4.5 crore doses administered in India: Harsh Vardhan

The Hindu  

More than 6 crore doses of COVID-19 vaccine have been sent to 76 nations, while 4.5 crore doses have been administered to beneficiaries in the country till now, Union Health Minister Harsh Vardhan said on Sunday. “Until this morning, nearly 4.5 crore COVID-19 vaccine doses have been given to the people in this country. More than six crore doses have …

Two More Covid-19 Vaccines Will be Available by May: National Task Force Chief
3 years, 9 months ago

Two More Covid-19 Vaccines Will be Available by May: National Task Force Chief

News 18  

Of the almost 30 vaccine candidates currently under various phases of trials in India, Russian Sputnik V should be available for use in the next 4-6 weeks, Head of the Operations Research Group of the COVID-19 Task Force Dr NK Arora told CNBC-News18 on Tuesday. “Zydus Cadila vaccine is next in line, should be available by end of May,” Dr …

Coronavirus | New challenges for COVID-19 vaccine trials in India
3 years, 11 months ago

Coronavirus | New challenges for COVID-19 vaccine trials in India

The Hindu  

On January 1, Pune-based Serum Institute’s Covishield vaccine was granted permission for restricted use, while Bharat Biotech’s Covaxin got a similar approval the next day with certain other riders. Effects of approval Now, with two vaccines approved for restricted use, how much more challenging will it be to enrol participants for clinical trials, particularly phase-3 trials that need 25,000–30,000 people? …

Nod for vaccines amid scare over new strains of Covid-19
3 years, 11 months ago

Nod for vaccines amid scare over new strains of Covid-19

Deccan Chronicle  

Hyderabad: Covaxin of the city-based Bharat Biotech was on Saturday recommended for approval for restricted use’ in ‘emergency situations’ in public interest with different mutant strains are emerging in SARS-CoV-2, the virus that causes Covid-19. On Saturday, the Subject Expert Committee of the Central Drugs Standard Control Organisation granted permission to Bharat Biotech in the ‘clinical trial’ mode and with …

Covid vaccine update: US panel endorses Moderna vaccine, AIIMS unable to find volunteers for Covaxin trials
4 years ago

Covid vaccine update: US panel endorses Moderna vaccine, AIIMS unable to find volunteers for Covaxin trials

India Today  

Coronavirus vaccine update: After rolling out the Pfizer coronavirus vaccine, US is now looking to approve the Moderna vaccine as well as coronavirus cases surge in the nation. Meanwhile in India, AIIMS-Delhi is reportedly finding it difficult to get enough volunteers for the Phase 3 trials of Covaxin, a Covid-19 vaccine candidate being developed by Hyderabad-based Bharat Biotech. US FDA …

Coronavirus | Foreign envoys visit Bharat Biotech, Biological E vaccine facilities in Hyderabad
4 years ago

Coronavirus | Foreign envoys visit Bharat Biotech, Biological E vaccine facilities in Hyderabad

The Hindu  

A delegation of foreign envoys visited manufacturing facilities of vaccine makers Bharat Biotech and Biological E in Hyderabad’s Genome Valley on Wednesday as part a visit to familiarise them with the work underway for Covid-19 vaccines. Bharat Biotech said a team comprising Ambassadors, High Commissioners and government representatives of 70 countries, from across the world, visited the facility and had …

Bharat Biotech’s Covaxin Phase-3 trials begin in State
4 years ago

Bharat Biotech’s Covaxin Phase-3 trials begin in State

The Hindu  

Covaxin trials are going to be successful in Karnataka and the State is fully prepared for the distribution of COVID -19 vaccine, Health and Medical Education Minister K. Sudhakar said on Wednesday. He was speaking after the launch of third phase clinical trials of Bharat Biotech’s Covaxin at the Vydehi Institute of Medical Science and Research Centre here. Experts are …

Covaxin, Bharat Biotech's coronavirus vaccine phase 3 trials commences in AIIMS
4 years ago

Covaxin, Bharat Biotech's coronavirus vaccine phase 3 trials commences in AIIMS

India TV News  

The phase-three human clinical trial of indigenously developed anti-coronavirus vaccine candidate Covaxin began at the AIIMS here on Thursday with Dr M V Padma Srivastava, the chief of Neurosciences Centre at the premier institute, and three other volunteers receiving the first dose. When contacted, Dr Srivastava said, "Covaxin is the first indigenously-developed anti-coronavirus vaccine and on top of that, my …

Coronavirus vaccine distribution faces logistics, supply chain challenges
4 years, 1 month ago

Coronavirus vaccine distribution faces logistics, supply chain challenges

Live Mint  

Observing that immunisation against COVID-19 involved several challenges, including logistics and supply chain for distribution of vaccine in the country, an expert has said there cannot be any lowering of guard on prevention of virus spread till a robust vaccine was available. While the government would do its job on procurement and distribution, the focus should be on keeping the …

Human trials of Russia’s Covid-19 vaccine candidate to begin in India this week
4 years, 1 month ago

Human trials of Russia’s Covid-19 vaccine candidate to begin in India this week

Hindustan Times  

Human trials for Sputnik-V, Russia’s vaccine candidate against the raging coronavirus disease pandemic is likely to start in India in the middle of this week, according to government officials. The Russian Direct Investment Fund had inked a deal with Dr. Reddy’s Laboratories, an Indian multinational pharmaceutical company headquartered in Hyderabad, for trials and distribution of its vaccine candidate in the …

Coronavirus | First batch of Sputnik V vaccine to arrive in Kanpur medical college for Phase 2, 3 trials
4 years, 1 month ago

Coronavirus | First batch of Sputnik V vaccine to arrive in Kanpur medical college for Phase 2, 3 trials

The Hindu  

The first batch of Russia’s Sputnik V vaccine for COVID-19 is likely to reach Kanpur’s Ganesh Shankar Vidyarthi Medical College by next week wherein the vaccine’s Phase 2 and Phase 3 human clinical trials will be conducted. The decision to conduct the human clinical trials of the vaccine was taken after Dr Reddy’s Laboratories got approval from the Drugs Controller …

Covid-19: Russia's Sputnik V vaccine to arrive in Kanpur medical college next week for Phase 2, 3 trials
4 years, 1 month ago

Covid-19: Russia's Sputnik V vaccine to arrive in Kanpur medical college next week for Phase 2, 3 trials

India Today  

Russia’s Sputnik V vaccine for coronavirus is likely to reach Kanpur’s Ganesh Shankar Vidyarthi Medical College by next week wherein the vaccine’s Phase 2 and Phase 3 human clinical trials will be conducted. The Drug Control General of India had granted approval to Russian Direct Investment Fund and Dr Reddy's Laboratories Ltd to conduct late-stage clinical trials of the Russian …

Bangladesh signs deal with India for 30 million doses of covid-19 vaccine
4 years, 1 month ago

Bangladesh signs deal with India for 30 million doses of covid-19 vaccine

Live Mint  

Bangladesh signed a deal with the Serum Institute of India on Thursday to buy 30 million doses of potential coronavirus vaccine being developed by British drugmaker AstraZeneca. "Whenever the vaccine is ready, the Serum Institute will give us 30 million doses in the first phase," health minister Zahid Maleque told reporters after the deal was signed in Dhaka. He said …

Coronavirus | Bharat Biotech plans to launch Covaxin in Q2 2021 upon approval from regulatory bodies
4 years, 1 month ago

Coronavirus | Bharat Biotech plans to launch Covaxin in Q2 2021 upon approval from regulatory bodies

The Hindu  

Bharat Biotech is planning to launch its vaccine for COVID-19 in the second quarter next year if it gets the requisite approvals from the Indian regulatory authorities, a top company official said. “If we get all the approvals after establishing strong experimental evidence and data, and efficacy and safety data in our last stage of trials, we aim to launch …

How close are we to getting a COVID-19 vaccine? | The Hindu In Focus podcast
4 years, 1 month ago

How close are we to getting a COVID-19 vaccine? | The Hindu In Focus podcast

The Hindu  

As India continues to walk the challenging path of tackling COVID-19, this month there has been some excitement with regard to possible vaccines. At present, there are four vaccines in India in various stages of clinical trials — Bharat Biotech’s Covaxin, a vaccine by Zydus Cadila, AstraZeneca and the University of Oxford’s Covishield. Globally, there are over 150 vaccine candidates …

Dr. Reddy's Laboratories shuts units after cyber attack
4 years, 2 months ago

Dr. Reddy's Laboratories shuts units after cyber attack

The Hindu  

India’s leading pharmaceutical company Dr. Reddy’s Laboratories has temporarily shut down some of its production facilities in the wake of a cyber attack in the early hours of Thursday. While a statement from the drugmaker said it had isolated all data centre services to take required preventive actions after the detection of a cyber attack, sources said as a precautionary …

DCGI approves Dr Reddy's request to conduct Phase 2, 3 clinical trials with Russia's Sputnik V COVD-19 vaccine
4 years, 2 months ago

DCGI approves Dr Reddy's request to conduct Phase 2, 3 clinical trials with Russia's Sputnik V COVD-19 vaccine

Firstpost  

After being denied their request to conduct a phase three clinical trial with Russia’s Sputnik V covid-19 vaccine and asked to submit a new request, the Controller General of Medicines of India has given Dr Reddy’s Laboratories its approval. After the first application was evaluated by the Subject Expert Committee on COVID-19 at Central Drugs Standard Control Organisation, the regulator …

Coronavirus | Vaccine supplies likely from early 2021: Health Secretary
4 years, 2 months ago

Coronavirus | Vaccine supplies likely from early 2021: Health Secretary

The Hindu  

The Union Health Ministry said on Tuesday that it was expecting COVID-19 vaccine supplies to be available from early next year. Addressing a press conference, Union Health Secretary Rajesh Bhushan said: “If all goes well, we are looking at vaccine supplies coming in the first quarter of next year. Combined trials Meanwhile, an expert panel at the Central Drugs Standard …

Dr Reddy's Asked To Resubmit Application for Both Phase 2,3 Trials of Russian Covid-19 Vaccine
4 years, 2 months ago

Dr Reddy's Asked To Resubmit Application for Both Phase 2,3 Trials of Russian Covid-19 Vaccine

News 18  

An expert panel at the Central Drugs Standard Control Organisation has asked Dr Reddy’s Laboratories to submit a revised protocol for conducting both phase 2 and phase 3 human clinical trials for the Russian vaccine against COVID-19, Sputnik V, in India, sources said Monday. The Hyderabad-based pharmaceutical company had applied to the Drugs Controller General of India late last week, …

Govt may need ₹80,000 cr for covid vaccine in next 1 year: Serum Institute CEO
4 years, 2 months ago

Govt may need ₹80,000 cr for covid vaccine in next 1 year: Serum Institute CEO

Live Mint  

NEW DELHI: The government may need ₹80,000 crore over the next one year for distribution of covid-19 vaccine to every person in India, Serum Institute of India chief executive officer Adar Poonawalla said on Saturday, calling it a "concerning challenge". The CEO of the world's largest vaccine maker also said all manufacturers and the government need to plan and guide …

Govt in Talks With to Russia for Possible Advancement of Covid-19 Vaccine in India: MoS Health
4 years, 3 months ago

Govt in Talks With to Russia for Possible Advancement of Covid-19 Vaccine in India: MoS Health

News 18  

The Centre is in consultations with the Russian government for exploring the possibility of cooperation between the two countries for advancing the COVID-19 vaccine in India, Parliament was told on Friday. The Central Drugs Standard Control Organisation has informed that it has received information about one COVID-19 vaccine developed and approved in Russia, Minister of State for Health Ashwini Choubey …

Covid-19 Vaccine: From China to India to UK, Let’s Know Where Coronavirus Research Stands
4 years, 3 months ago

Covid-19 Vaccine: From China to India to UK, Let’s Know Where Coronavirus Research Stands

News 18  

The coronavirus pandemic has altered the world but not in a good way. One of the vaccines candidates that is being developed by Sinovac Life Sciences Corporation in Beijing has shown remarkable results after the clinical trial in Brazil. As per China’s Global Times, China’s nasal spray vaccine is soon going to enter the phase of clinical trial. India’s local …

Hospitals selected to do Serum covid vaccine trials seek volunteers
4 years, 4 months ago

Hospitals selected to do Serum covid vaccine trials seek volunteers

Live Mint  

NEW DELHI: Hospitals conducting phase 2 clinical trial of Serum Institute of India’s covid-19 vaccine ‘Covishield’ have started seeking volunteers ahead of the trials which start this week. So far, out of the 17 sites that are conducting the trial, KEM Hospital Research Centre in Pune is ready with its list of volunteers but has not yet started human dosing …

Coronavirus Vaccine: Looking To Volunteer For Covaxin Trials? Know How To Register For The Trial At AIIMS
4 years, 5 months ago

Coronavirus Vaccine: Looking To Volunteer For Covaxin Trials? Know How To Register For The Trial At AIIMS

ABP News  

E-mail: [email protected] SMS or call on +91-7428847499. In a development that brought hopes amid the Covid-19 pandemic that has killed lakhs in the country so far, the All India Institute Of Medical Sciences -Delhi on Monday started recruitment drive of volunteers for conducting human clinical trials of the indigenously developed vaccine candidate Covaxin.According to the news agency PTI, premier medical …

Bangladesh to host late-stage trial of China’s Sinovac COVID-19 vaccine
4 years, 5 months ago

Bangladesh to host late-stage trial of China’s Sinovac COVID-19 vaccine

Live Mint  

Bangladesh's state medical research agency has approved a third-phase trial of a potential COVID-19 vaccine developed by China's Sinovac Biotech Ltd, as infections rise in the densely populated South Asian country. Sinovac has been looking for volunteers outside China as the number of coronavirus cases there has dwindled, said a member of Bangladesh’s national technical advisory committee to tackle COVID-19. …

Volunteers needed for clinical trial of Covid-19 vaccine Covaxin in AIIMS Delhi
4 years, 5 months ago

Volunteers needed for clinical trial of Covid-19 vaccine Covaxin in AIIMS Delhi

Hindustan Times  

The All India Institute of Medical Sciences in Delhi will start enrolling healthy individuals from Monday for conducting the human clinical trial of Covaxin, the indigenously developed Covid-19 vaccine candidate. AIIMS’s Ethics Committee gave its nod for a human clinical trial of Covaxin on Saturday This comes after AIIMS’s Ethics Committee gave its nod for a human clinical trial of …

AIIMS panel gives nod to begin human clinical trial of COVID-19 vaccine Covaxin from 20 July
4 years, 5 months ago

AIIMS panel gives nod to begin human clinical trial of COVID-19 vaccine Covaxin from 20 July

Firstpost  

Covaxin, Bharat Biotech’s COVID-19 vaccine candidate, has been developed in collaboration with the ICMR and NIV New Delhi: The AIIMS Ethics Committee on Saturday gave its nod for a human clinical trial of the indigenously developed COVID-19 vaccine candidate Covaxin following which the premier hospital is likely to begin the exercise by enrolling healthy volunteers from Monday. “The AIIMS Ethics …

AIIMS panel gives nod to human clinical trial of anti-coronavirus drug Covaxin
4 years, 5 months ago

AIIMS panel gives nod to human clinical trial of anti-coronavirus drug Covaxin

India Today  

The AIIMS Ethics Committee on Saturday gave its nod for a human clinical trial of the indigenously developed Covid-19 vaccine candidate Covaxin following which the premier hospital is likely to begin the exercise by enrolling healthy volunteers from Monday. "The AIIMS Ethics Committee gave its approval for starting the human clinical trial of the indigenously developed Covaxin today. Covid-19 vaccine …

COVID-19 vaccine in India: Government to set guidance document for trials of vaccines, treatment
4 years, 5 months ago

COVID-19 vaccine in India: Government to set guidance document for trials of vaccines, treatment

Firstpost  

No process in vaccine development trials will be skipped, but approvals to carry out multiple phases of trials parallelly may be given. “The guidance document outlines how to maintain rigour while also fast-tracking the process,” Swarup told the daily, adding that trials underway in India were “adaptive”. She added that no process in vaccine development trials would be skipped, but …

Discover Related